标题
Cost of decentralized
CAR
T‐cell production in an academic nonprofit setting
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-06-14
DOI
10.1002/ijc.33156
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- CRISPR/Cas9-based genome editing in the Era of CAR T cell immunotherapy
- (2019) January Salas-Mckee et al. Human Vaccines & Immunotherapeutics
- Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods
- (2019) Richard P. Harrison et al. CYTOTHERAPY
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- High Rate of Durable Complete Remission in Follicular Lymphoma after CD19 CAR-T cell Immunotherapy
- (2019) Alexandre V. Hirayama et al. BLOOD
- Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia
- (2019) Futian Ma et al. HEMATOLOGICAL ONCOLOGY
- GMP CAR-T cell production
- (2018) Adrian P. Gee BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors
- (2018) Richard P. Harrison et al. BIOTECHNOLOGY ADVANCES
- Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies—the German Cancer Consortium approach
- (2018) Angela M. Krackhardt et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar
- (2018) Richard P. Harrison et al. CYTOTHERAPY
- Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center
- (2018) Fenlu Zhu et al. CYTOTHERAPY
- CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications
- (2018) Ulrike Köhl et al. HUMAN GENE THERAPY
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation
- (2018) Feng Xie PHARMACOECONOMICS
- Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases
- (2018) Michael Schlander et al. VALUE IN HEALTH
- Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs
- (2018) George Dranitsaris et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia
- (2018) Elad Jacoby et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia
- (2018) John K. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Bringing down the cost of cancer treatment
- (2018) Elie Dolgin NATURE
- National Coverage Analysis of CAR-T Therapies — Policy, Evidence, and Payment
- (2018) Peter B. Bach NEW ENGLAND JOURNAL OF MEDICINE
- Scaling up the Manufacturing Process of Adoptive T Cell Immunotherapy
- (2018) Xiaofeng Dai et al. Biotechnology Journal
- Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia
- (2018) Melanie D. Whittington et al. JAMA Pediatrics
- The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
- (2017) Robert Hettle et al. HEALTH TECHNOLOGY ASSESSMENT
- FDA Approval of Tisagenlecleucel
- (2017) Peter B. Bach et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The high price of anticancer drugs: origins, implications, barriers, solutions
- (2017) Vinay Prasad et al. Nature Reviews Clinical Oncology
- Immunotherapy: Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers
- (2017) Vinay Prasad Nature Reviews Clinical Oncology
- Bioengineering Solutions for Manufacturing Challenges in CAR T Cells
- (2017) Nicole J. Piscopo et al. Biotechnology Journal
- Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy
- (2016) Ulrike Mock et al. CYTOTHERAPY
- Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors
- (2016) R Monjezi et al. LEUKEMIA
- Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Clinical manufacturing of CAR T cells: foundation of a promising therapy
- (2016) Xiuyan Wang et al. Molecular Therapy-Oncolytics
- Towards a commercial process for the manufacture of genetically modified T cells for therapy
- (2015) A D Kaiser et al. CANCER GENE THERAPY
- CAR T Cells for Solid Tumors
- (2014) Sunitha Kakarla et al. CANCER JOURNAL
- Rethinking clinical delivery of adult stem cell therapies
- (2014) Nuala Trainor et al. NATURE BIOTECHNOLOGY
- Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe
- (2014) Michael Schlander et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Exploiting the curative potential of adoptive T-cell therapy for cancer
- (2013) Christian S. Hinrichs et al. IMMUNOLOGICAL REVIEWS
- Drug Pricing and Value in Oncology
- (2010) P. M. Danzon et al. ONCOLOGIST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More